A biocompatible implant for a method of treating a reflux disease in a patient by preventing the cardia sphincter from sliding through the patient's diaphragm hiatus opening into the patient's thorax, so as to maintain a pressure support from the patient's abdomen that supports the patient's cardia sphincter. The biocompatible implant has a rigid shape, a circumference of at least 15 mm and is configured to be introduced into the patent's abdomen through a trocar, be fully invaginatable in the patient's fundus wall, and function as an implantable movement restricting device preventing the cardia sphincter from sliding through the patient's diaphragm, when implanted.

An apparatus for treating obesity of an obese patient having a stomach with a food cavity, the apparatus comprising at least one volume filling device adapted to be at least substantially invaginated by a stomach wall portion of the patient. The volume filling device is adapted to be placed inside the stomach wall with the outer surface of the volume filling device resting against the inside of the stomach wall, such that the volume of the food cavity is reduced in size by a volume substantially exceeding the volume of the volume filling device, the volume filling device having a maximum circumference of at least 30 millimeters.

A volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

An intraluminar method of treating obesity of a patient, having a stomach with a food cavity, is disclosed. The method comprises the steps of creating a pouch made of a stomach wall portion of the patient, closing the pouch by sutures, staples or a fixation device, and placing a volume filling device in the pouch before or after closing the pouch, and thus invaginating the volume filling device in the pouch such that an outer surface of the volume filling device rests against an outer surface of the stomach wall.

A device for treating obesity of a patient, the device comprising: at least one operable stretching device implantable in the patient and adapted to stretch a portion of the patient's stomach wall, and an implantable control unit for automatically controlling the operable stretching device, when the control unit and stretching device are implanted, to stretch the stomach wall portion in connection with the patient eating such that satiety is created.

An volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

A volume filling device for treatment of obesity is placed outside the stomach wall of the patient to reduce the inner volume of the stomach, thereby affecting the patient's appetite. By providing the volume filling device outside the stomach wall, contact with stomach acids is avoided, thereby increasing the life of the device.

A gastric restriction device for treating excessive weight or obesity in mammals. The gastric restriction devices includes a skirt having a left portion, a right portion, a top edge with a first indentation located at a center of the top edge, and a bottom edge with a second indentation located at a center of the bottom edge. The skirt has a narrow surface located between the first indentation and the second indentation and a broad surface formed from the left portion connecting to the right portion. The skirt is configured to envelop and fit a stomach of a mammal. The gastric restriction devices includes a first attachment device and a second attachment device. The second attachment device is adapted to engage the first attachment device so that the skirt envelops and fits the stomach of the mammal.

An apparatus for the treatment of acid reflux disease has an implantable movement restriction device adapted to be at least partly invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device has a size of at least 125 mm.sup.3 and a circumference of at least 15 mm.

An apparatus for treating reflux disease of a human patient. The apparatus comprising an implantable movement restriction device, having an outer surface that includes a biocompatible material. The movement restriction device is adapted to rest against and to be kept in place contacting the stomach fundus wall, without restricting food passage in the food passageway when implanted and in function, and without injuring the stomach fundus wall in a position between the patient's diaphragm and the cardia sphincter. The movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is thereby restricted, when the movement restriction device is implanted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax. The movement restriction device is adapted to contact directly or indirectly the diaphragm muscle to prevent such sliding of the cardia through the patient's diaphragm, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device having a size, when implanted and in function such that the functional movement restriction device can be completely invaginated by the stomach fundus of the human patient, and of at least 125 mm.sup.3, and a circumference of at least 15 mm.